Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Core Operating Income Margin: 40.1% in FY2025, up 1.4 pts from a year earlier.
Latest, FY2025
40.1%
Period ended Dec 31, 2025
Change on a year earlier
+1.4 pts
38.7% in FY2024
History
4 years
Since FY2022
Sources
3
Documents cited below
Where the FY2025 figure comes from
“|| % of net sales | 37.0 | 36.9 | 40.1 | 38.7”
Source: Novartis Form 6-K (0001114448-26-000007) ↗
Reported in Form 6-K.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Core Operating Income Margin (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 40.1% | +1.4 pts | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2024 | Dec 31, 2024 | 38.7% | +2.7 pts | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2023 | Dec 31, 2023 | 36.0% | +0.9 pts | Novartis Form 6-K (0001370368-25-000007) ↗ |
| FY2022 | Dec 31, 2022 | 35.1% | – | Novartis Form 6-K (0001370368-24-000007) ↗ |
Cite this data
StockData. (2026). Novartis Core Operating Income Margin (%), annual FY2022–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/core-operating-margin-pct
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.